An Open-label, Balanced, Randomized, Five-treatment, Five-period, Five-sequence, Multiple Oral Dose, Crossover Comparative Bioavailability Study of Different Strengths of Carbidopa/Levodopa Extended-release Tablets With Carbidopa and Levodopa Tablets in Normal, Healthy Adult Human Subjects Under Fasting and Fed Conditions
Latest Information Update: 31 Aug 2026
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Shanghai WD Pharmaceutical
Most Recent Events
- 26 Aug 2026 Status changed from recruiting to completed.
- 23 Nov 2021 New trial record